ContraFect Corporation

Company Overview

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.

Pipeline

Stock Overview

Symbol
CFRX
Exchange
Nasdaq
Market Cap
169.47m
Last Price
$6.095
52-Week Range
$2.693 - $13.399

07/15/2020 12:30 PM EDT

Investor Relations

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com